beta-carboline-3-carboxylic acid ethyl ester has been researched along with zaprinast in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Coste, H; Daugan, A; Grondin, P; Hyafil, F; Kirilovsky, J; Labaudinière, R; Le Monnier de Gouville, AC; Ruault, C | 1 |
Leeson, PD; Young, RJ | 1 |
1 review(s) available for beta-carboline-3-carboxylic acid ethyl ester and zaprinast
Article | Year |
---|---|
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
Topics: Animals; Chemical Phenomena; Drug Discovery; Humans; Hydrophobic and Hydrophilic Interactions | 2018 |
1 other study(ies) available for beta-carboline-3-carboxylic acid ethyl ester and zaprinast
Article | Year |
---|---|
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Pressure; Carbolines; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Hydantoins; Indicators and Reagents; Isomerism; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Tadalafil | 2003 |